Table 3.
Data for patients over 60y in studies designed for younger patients.
| Study | Nb pts | Age | Protocole | Response | Survival | Toxicity | Comments | Ref |
|---|---|---|---|---|---|---|---|---|
| Weekes (2002) | 56 | ≥60 | ChlVPP or ChlVPP/ABV | PR+CR 84% | 5y OS 30% or 67% | NR | age only pronostic factor for pts >60 | 54 |
| Ballova (2005) | 68 | 66–75 Advanced | COPP/ABVD vs BEACOPP - baseline | CR 76% | 5y FFTF 55% vs 74% |
TRM 2% vs 8% | RT to bulky and residual mass(26%) | 51 |
| Klimm (2007) | 89 | 60 (med 65) early unfavorable | COPP/ABVD + EFRT/IFRT | CR/CRU 93,5% | 5y FFTF 64% vs 70% |
2% of TRM related to EFRT | negative impact of EFRT vs IFRT | 55 |
| Evens (2013) | 45 | ≥60 | ABVD x 6–8 vs S.V x 12 w | CR/CRU ABVD 65% S.V 62% |
3y OS 73% 3y FFS 56% |
TRM 9% | 24% lung tox. RT in 8,7% ABVD pts 43 % S.V pts |
16 |
| Böll (2013) | 117 | 65–70 med 65 stage I–IIA | ABVD x 4 IFRT 20–30 gy |
CR 89% | 5y PFS 75% | TRM 5% grade 3–4 68% |
GHSG H10–H11 studies | 45 |